Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India.

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or ...

Nasopharyngeal carcinoma (NPC) is a rare, aggressive form of head and neck cancer that originates in the nasopharynx, the ...

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab ...

News on Telangana Today, Metastatic nasopharyngeal carcinoma (RM-NPC) latest news, Metastatic nasopharyngeal carcinoma (RM-NPC) news, | Telangana Today ...

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for ...

Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, ...

Dr. Reddy’s Laboratories on Thursday announced the launch of Toripalimab in India to treat adults with Nasopharyngeal ...

Dr. Reddy’s Laboratories has launched Toripalimab, a New Biological Entity (NBE) in the domestic market. “The launch of ...

Dr. Reddy's Laboratories Ltd. (RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved ...

Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. This drug is designed to treat adults suffering ...